Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glucose Control Clear all
Completed Phase 4 Interventional

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Aspart
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

NCT00036192
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
FK614
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
25 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
36
States / cities
Ozark, Alabama • Tucson, Arizona • Cypress, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Early Phase 1 Interventional

Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin

NCT01929798
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
portable Artificial Pancreas
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

NCT00111540
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Not applicable Interventional

The Breakfast Study

NCT05986097
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Breakfast
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 12, 2026, 2:56 AM EDT
Terminated Not applicable Interventional

OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus

NCT02054650
View directory record Official record
Conditions
Chronic Low Back Pain, Type 2 Diabetes Mellitus
Interventions
Osteopathic Manual Treatment (OMT), Sham OMT
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 12, 2026, 2:56 AM EDT
Not listed Not applicable Interventional

Tu Salud (Your Health) Randomized Control Study in Patients With Diabetes Using a Mobile App.

NCT03556605
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
OneTouch Reveal® Mobile APP system, Current Blood Glucose Monitor
Other
Lead sponsor
LifeScan
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Results available

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02367066
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AR-C165395XX, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Not applicable Interventional

CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes

NCT01416766
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus
Interventions
Self-monitoring-nurse-primary care provider feedback loop
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

NCT03667053
View directory record Official record
Conditions
Hypoglycemia
Interventions
dasiglucagon, placebo, GlucaGen HypoKit
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Escondido, California • New Haven, Connecticut • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

NCT04529473
View directory record Official record
Conditions
Pre Diabetes, Impaired Glucose Tolerance, Insulin Sensitivity, Insulin Resistance, Glucose Metabolism Disorders, Metabolic Syndrome
Interventions
Eubacterium hallii, Placebo
Dietary Supplement · Other
Lead sponsor
Atlantia Food Clinical Trials
Industry
Eligibility
21 Years to 69 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

NCT00147719
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam hydrochloride
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
46
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Carmichael, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

CANVAS - CANagliflozin cardioVascular Assessment Study

NCT01032629
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
Interventions
Placebo, Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
58
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Barley Beta-glucan, Glycemic Control, and Appetite

NCT06146322
View directory record Official record
Conditions
Diet, Healthy, Blood Sugar; High, Diabetes, Appetite and General Nutritional Disorders, Appetitive Behavior
Interventions
WR, LB, MB, HB, WR+50g HFCS, LB + 50 g HFCS, MB + 50 g HFCS, HB + 50 g HFCS
Other
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 12, 2026, 2:56 AM EDT
Not listed Phase 3 Interventional

A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

NCT01824407
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Electrohydraulic-generated shock wave, Sham device plus standard of care
Device
Lead sponsor
SANUWAVE, Inc.
Industry
Eligibility
22 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Exenatide in Patients With Diabetic Neuropathy

NCT00855439
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
Interventions
Exenatide, Glargine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 12, 2026, 2:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Lifestyle Interventions for Long Term Diabetes Control

NCT00364312
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
diet and physical activity
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2006 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

NCT00982228
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
59
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 12, 2026, 2:56 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers

NCT00330265
View directory record Official record
Conditions
Foot Ulcer, Diabetes
Interventions
KC-002, Conventional Wound Therapy
Device · Other
Lead sponsor
KeraCure
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

NCT02455011
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes
Interventions
REMD-477
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NCT03336528
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Degludec, Glargine, Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Can Group Visits Improve Outcomes of Veterans With Diabetes

NCT00286741
View directory record Official record
Conditions
Diabetes, Hypertension
Interventions
Diabetes Group Management Visits
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Durham, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Targeted CPAP Therapy for Obstructive Sleep Apnea in Pregnancy

NCT02755831
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
CPAP, Pre-natal care
Device · Other
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older · Female only
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 12, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CT-868, Placebo, Victoza
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 12, 2026, 2:56 AM EDT